articleTop 1% cited
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
Leukemia · 2009 · Vol. 23(6) · pp. 1054–1061
Andreas Hochhaus✉(Heidelberg University)S G O'Brien(Newcastle University)François Guilhot(Inserm)Brian Druker(Oregon Health & Science University)Susan Branford(South Australia Pathology)Letizia Foroni(Hammersmith Hospital)John M. Goldman(Hammersmith Hospital)Martin Müller(University Hospital Heidelberg)Jerald P. Radich(Fred Hutch Cancer Center)Marc S. Rudoltz(Novartis (Switzerland))Manisha Mone(Novartis (Switzerland))Insa Gathmann(Novartis (Switzerland))Timothy P. Hughes(South Australia Pathology)Richard A. Larson(University of Chicago)for the IRIS Investigators
Chronic Myeloid Leukemia TreatmentsEosinophilic Disorders and SyndromesChronic Lymphocytic Leukemia ResearchImatinibMedicineImatinib mesylateMyeloid leukemiaInternal medicineRandomized controlled trialCytarabineOncologyAlpha interferonSurgery
MeSH terms
Imatinib MesylateBenzamidesFollow-Up StudiesHeart FailureHumansPiperazinesPyrimidinesRemission InductionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSurvival AnalysisNeoplasms, Second PrimaryTreatment OutcomeDisease Progression
Citations
843
FWCI
47.76
field-weighted impact
References
33
Percentile
100%
vs. same field & year
Citations per year
Cited by
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Blood · 2013 · 1,979 citations
References
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
Leukemia · 2004 · 685 citations
The National Comprehensive Cancer Network
Cancer · 1998 · 16,869 citations
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Nature Medicine · 1996 · 3,643 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.